VIVA-MIND
A New Alzheimer's Research Trial
Funded by the National Institute on Aging (NIA), and sponsored by Vivoryon Therapeutics, the VIVA-MIND clinical trial is evaluating whether the investigational oral drug varoglutamstat is safe and can slow down or halt the progression of mild Alzheimer’s disease (AD). Join our compensated study today!
Fast Facts
- Mild Cognitive Impairment or Mild AD
- Currently Stable On Certain AD Medication(s)
- 50-89 Years Old
- Compensation Provided
- Conducted At 20+ Sites Nationwide
Study Background
The VIVA-MIND trial is designed to determine if the study drug, varoglutamstat, can stabilize or slow memory and thinking problems that increase in mild AD.
In mild AD, a specific and toxic form of the amyloid protein accumulates in the brain. This toxic protein, called N3pE, appears to damage brain cells and surrounding tissues, and activates a strong inflammatory response.
The amyloid protein N3pE is not found in healthy individuals and increases with AD progression. VIVA-MIND researchers suspect that N3pE may play a major role in the decline of memory and thinking skills in mild AD. Varoglutamstat is designed to specifically target and reduce N3pE.
If you have been diagnosed with mild cognitive impairment, mild AD or mild probable AD, and you have a study partner (someone who knows you well) who can participate with you for 20 months, you may qualify to join the VIVA-MIND study. Your participation may help researchers develop better treatments for AD. Enroll today!
Study Background
The VIVA-MIND trial is designed to determine if the study drug, varoglutamstat, can stabilize or slow memory and thinking problems that increase in mild AD.
In mild AD, a specific and toxic form of the amyloid protein accumulates in the brain. This toxic protein, called N3pE, appears to damage brain cells and surrounding tissues, and activates a strong inflammatory response.
The amyloid protein N3pE is not found in healthy individuals and increases with AD progression. VIVA-MIND researchers suspect that N3pE may play a major role in the decline of memory and thinking skills in mild AD. Varoglutamstat is designed to specifically target and reduce N3pE.
If you have been diagnosed with mild cognitive impairment, mild AD or mild probable AD, and you have a study partner (someone who knows you well) who can participate with you for 20 months, you may qualify to join the VIVA-MIND study. Your participation may help researchers develop better treatments for AD. Enroll today!
Study Locations
Additional Information
You may qualify for this study if you meet the following criteria.
Key Criteria:
- Aged 50-89
- Diagnosed Mild Cognitive Impairment (MCI), Mild AD, or probable Mild AD
- Stable on current FDA-approved AD medication(s) acetylcholinesterase inhibitors (AchEI) with or without memantine for at least four months prior to screening
- Living in the community (not in a skilled nursing facility)
- Able to identify a study partner who has regular contact with you and can accompany you to clinic visits
- Willing to participate in the VIVA-MIND study for up to 20 months
A potential participant will first go through a screening process to see if they are eligible to take part in the clinical trial. The study screening process includes conducting memory and thinking tests; a physical examination; heart rhythm and electrical brain activity tests; brain imaging using MRI; and blood and spinal fluid tests.
Once enrolled, half of the participants are given the study drug, varoglutamstat, and half are given an inactive pill (called a placebo), which is taken orally two times daily.
Study participants, accompanied by a study partner, visit the study clinic up to 12 times after enrollment in the trial. Trial participation will last up to 20 months.
